One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
Unlike GLP-1, liraglutide is not cleared by the glomerulus and its pharmacokinetic is not altered in patients with mild renal impairment. The aim of our study was to analyze the effects of liraglutide on renal function in patients with type 2 diabetes. A twelve-month longitudinal prospective post-marketing study was performed. According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min). BMI, glucose, HbA1c, serum creatinine, microalbuminuria, and eGFR were evaluated at baseline and after 12 months of treatment. A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category. Concerning renal function, creatinine levels had a trend to decrease in both groups. eGFR did not change in Group A, while it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters. Moreover, seven out of 41 patients of Group B had increased eGFR levels which reached the normal values (>90 ml/min). At baseline, five patients had pathological microalbuminuria, but at 12 months three of them returned to normal albuminuria (p < 0.006). Total microalbuminuria levels improved in both groups (p < 0.02). According to preliminary data in animals, our study shows that liraglutide is effective in preserving eGFR in diabetic patients, increasing it in those with reduced renal function. This was associated with a decrease of frequency of patients positive to microalbuminuria. Further studies are needed to confirm these data.
['Zavattaro|Marco|M|', 'Caputo|Marina|M|', 'Samà|Maria Teresa|MT|', 'Mele|Chiara|C|', 'Chasseur|Luisa|L|', 'Marzullo|Paolo|P|', 'Pagano|Loredana|L|', 'Mauri|Maria Grazia|MG|', 'Ponziani|Maria Chantal|MC|', 'Aimaretti|Gianluca|G|', 'Prodam|Flavia|F|']
D000328:Adult D000368:Aged D003924:Diabetes Mellitus, Type 2 D003928:Diabetic Nephropathies D005919:Glomerular Filtration Rate D006801:Humans D007004:Hypoglycemic Agents D000069450:Liraglutide D008875:Middle Aged D010865:Pilot Projects D011446:Prospective Studies
Liraglutide Diabetes Human Kidney